Amyvid

Positron Emission Tomography, Alzheimer's Disease
Treatment
3 FDA approvals
20 Active Studies for Amyvid

What is Amyvid

Florbetapir (18F)The Generic name of this drug
Treatment SummaryFlorbetapir (18F) is a radioactive drug used to create images of the brain and check for beta amyloid plaque, a protein associated with Alzheimer's Disease. It is sold under the brand name Amyvid and is used in positron emission tomography (PET) scans to help detect Alzheimer's in adults with cognitive impairment. The active ingredient, fluorine-18, has a half-life of 110 minutes, which allows it to accumulate enough in the brain to be detected.
Amyvidis the brand name
Amyvid Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Amyvid
Florbetapir (18F)
2012
1

Approved as Treatment by the FDA

Florbetapir (18F), also known as Amyvid, is approved by the FDA for 3 uses including Alzheimer's Disease (AD) and Positron Emission Tomography .
Alzheimer's Disease (AD)
Positron Emission Tomography
Alzheimer's Disease

Effectiveness

How Amyvid Affects PatientsWhen injected into the bloodstream, florbetapir F 18 is able to cross the blood-brain barrier and spread throughout the brain. As the brain processes the drug, the amount of florbetapir F 18 decreases in different areas - more florbetapir F 18 stays in areas that contain clumps of a protein called beta-amyloid, compared to other areas that do not.
How Amyvid works in the bodyFlorbetapir (18F) is a special drug that helps to diagnose Alzheimer's Disease. It contains a radioactive element called fluorine-18. This element binds to a molecule called florbetapir, which sticks to the beta-amyloid plaque in the brain. This plaque is linked to Alzheimer's Disease. The fluorine-18 has a short lifespan of 110 minutes, which gives it enough time to collect in the brain before it disappears.

When to interrupt dosage

The sum of Amyvid depends upon the identified condition. The measure of dosage fluctuates, in keeping with the delivery technique stated in the accompanying table.
Condition
Dosage
Administration
Positron Emission Tomography
21.6 mCi/mL, , 51.3 mCi/mL, 51.0 mCi/mL
Intravenous, , Injection, solution, Injection, solution - Intravenous
Alzheimer's Disease
21.6 mCi/mL, , 51.3 mCi/mL, 51.0 mCi/mL
Intravenous, , Injection, solution, Injection, solution - Intravenous

Warnings

There are 20 known major drug interactions with Amyvid.
Common Amyvid Drug Interactions
Drug Name
Risk Level
Description
Acrivastine
Minor
Florbetapir (18F) may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Albutrepenonacog alfa
Minor
Florbetapir (18F) may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Almasilate
Minor
Florbetapir (18F) may decrease the excretion rate of Almasilate which could result in a higher serum level.
Antihemophilic factor (recombinant), PEGylated
Minor
Florbetapir (18F) may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.
Antithrombin III human
Minor
Florbetapir (18F) may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.
Amyvid Toxicity & Overdose RiskThe most common side effect of this drug is headache (2%), followed by aches and pains (less than 1%), high blood pressure, tiredness, nausea, and skin reactions at the injection site (all less than 1%).

Amyvid Novel Uses: Which Conditions Have a Clinical Trial Featuring Amyvid?

41 active investigations are being conducted to assess the utility of Amyvid in Positron Emission Tomography imaging.
Condition
Clinical Trials
Trial Phases
Alzheimer's Disease
38 Actively Recruiting
Phase 4, Phase 2, Phase 3, Not Applicable, Phase 1
Positron Emission Tomography
1 Actively Recruiting
Early Phase 1

Patient Q&A Section about amyvid

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is amyvid used for?

"Use of Amyvid in these patients is indicated to help rule out AD and to provide an indication of the density of β-amyloid neuritic plaques."

Answered by AI

Is amyvid FDA approved?

"The FDA has approved Amyvid™ (florbetapir F 18 injection) for use in patients being evaluated for Alzheimer's disease and other causes of cognitive decline. Amyvid is a radioactive diagnostic agent that is injected into a vein and scans the brain for amyloid plaques. The presence of amyloid plaques is one marker for Alzheimer's disease."

Answered by AI

Who owns amyvid?

"Indianapolis, IN: Avid Radiopharmaceuticals Inc; March 2012.[2]

Amyvid is a trademark of Eli Lilly and Company. Amyvid is a radioactive diagnostic agent used to measure amyloid plaques in the brain. Avid Radiopharmaceuticals Inc manufactures Amyvid."

Answered by AI

When was amyvid FDA approved?

"The approval date for this document is 4/6/2012. The date of this document is 5/3/2012."

Answered by AI

Clinical Trials for Amyvid

Have you considered Amyvid clinical trials? We made a collection of clinical trials featuring Amyvid, we think they might fit your search criteria.
Have you considered Amyvid clinical trials? We made a collection of clinical trials featuring Amyvid, we think they might fit your search criteria.
Have you considered Amyvid clinical trials? We made a collection of clinical trials featuring Amyvid, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top